425 related articles for article (PubMed ID: 23102014)
1. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
[TBL] [Abstract][Full Text] [Related]
2. [Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
Leon P; Saint F; Audenet F; Roumiguié M; Allory Y; Loriot Y; Masson-Lecomte A; Pradère B; Seisen T; Traxer O; Xylinas E; Roupret M; Neuzillet Y
Prog Urol; 2022 Apr; 32(5):299-311. PubMed ID: 35151545
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
Descazeaud A; Mignard JP; Davin JL; Irani J
Prog Urol; 2009 Oct; 19(9):624-31. PubMed ID: 19800553
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and management of adverse events occuring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): review of the Cancer Committee of the French Association of Urology].
Neuzillet Y; Rouprêt M; Wallerand H; Pignot G; Larré S; Irani J; Davin JL; Moreau JL; Soulié M; Pfister C;
Prog Urol; 2012 Dec; 22(16):989-98. PubMed ID: 23178094
[TBL] [Abstract][Full Text] [Related]
5. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
[TBL] [Abstract][Full Text] [Related]
6. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
7. Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study.
Khan W; Zugail AS; Blanc E; Neuziller Y; Lebret T
Prog Urol; 2020 Feb; 30(2):75-79. PubMed ID: 31953014
[TBL] [Abstract][Full Text] [Related]
8. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
[TBL] [Abstract][Full Text] [Related]
9. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
10. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
[TBL] [Abstract][Full Text] [Related]
11. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
13. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
14. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
15. [Intravesical therapy: Influence on superficial bladder cancer progression].
García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Rodríguez Robles L; Martín Benito JL; San Martín Blanco A; Regadera Sejas J
Arch Esp Urol; 2007; 60(1):31-5. PubMed ID: 17408169
[TBL] [Abstract][Full Text] [Related]
16. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
[No Abstract] [Full Text] [Related]
17. [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.].
Chantada-Abal V; Chantada-Tirado C; Lamas-Díaz L; Caramés-Masana F; Villegas-Piguave AD; Villar-Vázquez N
Arch Esp Urol; 2018 May; 71(4):453-457. PubMed ID: 29745935
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical instillation for bladder tumors].
Rivière A; Ploussard G; Desgranchamps F
Rev Prat; 2014 Dec; 64(10):1388-9. PubMed ID: 25665319
[No Abstract] [Full Text] [Related]
19. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
Tapiero S; Helfand A; Kedar D; Yossepowitch O; Nadu A; Baniel J; Lifshitz D; Margel D
Urology; 2018 Aug; 118():107-113. PubMed ID: 29792974
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment].
Lailler G; Neuzillet Y; Rouanne M; Lebret T
Prog Urol; 2016 Feb; 26(2):79-82. PubMed ID: 26653577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
